Agilect, Promotion Season Now in Store and Free Sample for Testing with Factory Price
- Chemical Name: Rasagiline mesylate
- CAS No.: 161735-79-1
- Molecular Fomula: :C13H17NO3S
- Molecular weight:267.34398
- Appearance: white powder
- Sample:Available
Send Inquiry
Download Quotation
Description of Agilect
Rasagiline is a selective irreversible MAO-B inhibitor. Rasagiline is an Antiparkinsonian agent.
Basic Info of Agilect
Basic Info
Numbering system
Properties
Safety Info
Basic Info
Chemical Name | Rasagiline Mesylate |
Synonyms | methanesulfonic acid,(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine;Rasagiline mesylate;(R)-N-(Prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine methanesulfonate; |
CAS No. | 161735-79-1 |
Molecular Formula | C13H17NO3S |
Molecular Weight | 267.34400 |
PSA | 74.78000 |
LogP | 2.87240 |
Numbering system
MDL number | MFCD08460604 |
Properties
Appearance & Physical State | White powder |
Density | 1.05 g/cm3 |
Boiling Point | 305.5ºC at 760 mmHg |
Melting Point | 155-158ºC |
Flash Point | 146.8ºC |
Vapor Pressure | 0.000816mmHg at 25°C |
Safety Info
Safety Statements | S26; S37/39 |
HS Code | 2921499090 |
WGK Germany | 3 |
Risk Statements | R36/37/38 |
Hazard Codes | Xi |
What is Rasagiline mesylate?
- With the progress of science and technology and the development of society, chemical products have invariably permeated our daily lives, in medicine, food, cosmetics, electronics, industry, and other areas, becoming an essential part of our lives. One such product is Rasagiline mesylate which has developed particularly rapidly in recent years. Do you know about Rasagiline mesylate?
- The official answer:Rasagiline mesylate was developed by Teva Pharmaceutical Industries, Israel, and was first approved for marketing by the European Medicines Agency (EMA) on February 21, 2005, and by the U.S. Food and Drug Administration (FDA) on May 16, 2006. It is indicated for monotherapy (without levodopa) in patients with primary Parkinson’s disease and as an adjunct to levodopa in Parkinson’s patients with end-of-dose fluctuations. Rasagiline mesylate is an irreversible monoamine oxidase inhibitor that reduces the breakdown of dopamine through selective inhibition of monoamine oxidase and elevates extracellular levels of dopamine in the high stratum of the brain, and the elevated dopamine levels reduce the symptoms of Parkinson’s disease. Rasagiline mesylate is 5-10 times stronger than selegiline (a first-generation monoamine oxidase inhibitor, including Sigfrancine, Midolpir, and Goldspine), and also has an improvement effect on patients who experience a decline in the efficacy of long-term dopamine preparations. In addition, the metabolite of Rexagiline is an inactive non-amphetamine substance with few side effects. More importantly, unlike other anti-Parkinsonian drugs, rasagiline mesylate also has neuroprotective effects. When combined, it can optimize levodopa treatment effects to further effectively control symptoms and reduce motor complications. According to 2017 US IMS data, the anti-Parkinson’s treatment market was $2.056 billion in the global top 500 best-selling drug market, an increase of 3.73% from the previous year.
What’s the application of Rasagiline mesylate?
- The pharmacological mechanism of Rexagiline: Rexagiline is a potent, highly selective, irreversible monoamine oxidase-B inhibitor that inhibits dopamine degradation, increases dopamine accumulation, promotes dopamine release, and improves clinical symptoms in PD patients. It has a novel chemical structure, and the novel chemical structure is intended to improve the deficiencies of the initial generation MAO-B inhibitor therapy. Slesagiline is a first-generation MAO-B inhibitor, and its metabolites include amphetamine derivatives that can cause adverse effects, such as affecting patients’ sleep. The metabolites of rasagiline, on the other hand, do not contain amphetamine derivatives. In vitro studies have confirmed that the metabolite of rasagiline, amino in an, has neuroprotective effects.
Conclusion
Sincere to the customer and in good faith of quality is our forever followed motto. It’s the basement to be a human and do business. We take all responsibility for our products and service sincerely. We are a company integrating R&D, production, and sales. The design, research, and development of pharmaceutical intermediates including more than 330 kinds of pharmaceutical intermediates such as Anti-infectives, Cardiovascular and Cerebrovascular Systems, Digestive System, Santi-tumor, Nervous System, Geriatric Drugs, and Gynecological Drugs. At the same time, we have more than 4,000 factories in strategic cooperation with nearly 50,000 chemical products, so we can provide you with a one-stop purchasing service, which greatly saves customers’ procurement costs and time.
Keywords of Rasagiline mesylate
Agilect , 161735-79-1, buy Agilect, Rasagiline mesylate supplier, purchase Agilect, Agilect cost, Agilect manufacturer, order Agilect, high pur Agilect Agilect